Akero Therapeutics's total assets for Q2 2025 were $1.11B, a decrease of -4.04% from the previous quarter. AKRO total liabilities were $83.33M for the fiscal quarter, a 15.75% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.